Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.67 Consensus Target Price from Brokerages

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) have been assigned an average rating of "Buy" from the eight research firms that are covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $25.67.

A number of equities research analysts have recently issued reports on ATXS shares. Citizens Jmp upgraded shares of Astria Therapeutics to a "strong-buy" rating in a research report on Friday, January 31st. HC Wainwright reiterated a "buy" rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Thursday, January 23rd. Oppenheimer raised their price objective on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a research note on Thursday, November 14th. Finally, JMP Securities began coverage on shares of Astria Therapeutics in a research note on Friday, January 31st. They set an "outperform" rating and a $26.00 price objective for the company.

Astria Therapeutics Stock Performance

NASDAQ:ATXS traded up $0.03 during mid-day trading on Friday, reaching $7.14. The stock had a trading volume of 149,439 shares, compared to its average volume of 286,310. The firm has a market capitalization of $402.66 million, a price-to-earnings ratio of -3.38 and a beta of 0.67. Astria Therapeutics has a twelve month low of $7.03 and a twelve month high of $16.90. The business has a 50 day simple moving average of $8.64 and a 200 day simple moving average of $10.29.

Institutional Trading of Astria Therapeutics

Several institutional investors have recently made changes to their positions in ATXS. New York State Common Retirement Fund grew its stake in shares of Astria Therapeutics by 67.0% during the 4th quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company's stock valued at $96,000 after buying an additional 4,300 shares during the period. Quest Partners LLC lifted its holdings in shares of Astria Therapeutics by 180.8% during the 3rd quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company's stock valued at $99,000 after acquiring an additional 5,798 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Astria Therapeutics during the 4th quarter valued at $107,000. PDT Partners LLC acquired a new position in shares of Astria Therapeutics during the 3rd quarter valued at $140,000. Finally, SG Americas Securities LLC acquired a new position in shares of Astria Therapeutics during the 3rd quarter valued at $155,000. 98.98% of the stock is owned by hedge funds and other institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.